Elekta Expands Market and Treatment Application of Brachytherapy with Acquisition of iCAD, Inc.’s Xoft Business
Summary
Xofts unique technology, which uses a miniaturized low energy X-ray source instead of a radioactive isotope, can be used in a variety of clinical settings with minimal shielding. John Lapré, President Brachy and Neuro Solutions at Elekta, said: “Bringing Xoft’s technology into our portfolio offers exciting prospects to grow the adoption of brachytherapy and provide greater access to patients eligible for this treatment. We will be able to provide a wider range of radiation therapy options that are tailored to the specific needs and preferences of the clinics we support, while helping to reduce their operational costs – since no extensive shielding is needed – and minimize their logistical challenges such as importing radioactive material.” The Xoft System has an installed base of more than 100 systems, compared with 1,900 Elekta Flexitron afterloaders. Elekta solutions are used in more than 120 countries and through its global network, the Xoft technology will now be able to reach more patients in need of personalized, precision radiation therapy. The Xoft System is FDA-cleared and CE-marked for the treatment of cancer anywhere in the body using a miniaturized X-ray source to deliver a precise, concentrated dose of radiation directly to a tumor site.
Classifications
AskAI Classifications
LabelsLinked Companies
